Legend Biotech Corporation (NASDAQ:LEGN) is one of the best biotech stocks with high potential. On October 3, TD Cowen analyst Yaron Werber reiterated a Buy rating on Legend Biotech Corporation (NASDAQ:LEGN), keeping the price target at $62.00.
The analyst supported the optimistic rating with the company’s future growth potential and strategic positioning.
He stated that while Legend Biotech Corporation (NASDAQ:LEGN) is experiencing supply constraints with its Carvykti product at present, management is confident about the company’s potential to overcome these limitations by the end of 2025, supported by planned capacity expansions at key sites.
According to him, this confidence can be seen in Legend Biotech Corporation’s (NASDAQ:LEGN) expectations to meet the consensus sales target of $1.9 billion for the fiscal year 2025.
Legend Biotech Corporation (NASDAQ:LEGN) is a clinical-stage company that develops, discovers, manufactures, and commercializes novel therapies for oncology and other indications.
It develops advanced cell therapies across an elaborate range of technology platforms. The company operates in the US, China, and other geographical segments.
While we acknowledge the potential of LEGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
